BioCentury | May 23, 2019
Tools & Techniques

As polygenic risk scores mature, opportunities emerge for disease interception

With comprehensive genetic risk profiling inching closer to clinical use, the biggest opportunity for drug developers could be the new territory it opens up in disease prevention and interception, particularly for common diseases. Much of...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
BioCentury | Oct 31, 2018
Distillery Techniques

Disease models

...used to screen therapies for invasive lobular breast carcinoma. Mice engineered to express mutant, inactive CHD1...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

...AR-V7 ATF6 AR-V7-expressing CRPC 2901 DNAJ; AR-V7 HSF1 AR-V7-expressing CRPC 2901 Histone modification Proliferation regulation CHD1...
BioCentury | Mar 16, 2018
Clinical News

Sanofi, Regeneron offer lower Praluent price on heels of ODYSSEY data

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from the 18,924-patient Phase III ODYSSEY OUTCOMES trial showing that Praluent alirocumab given on top of statins lowered the risk of major adverse cardiovascular events...
BioCentury | Mar 10, 2018
Clinical News

Sanofi, Regeneron offer lower Praluent price on heels of ODYSSEY data

Armed with cardiovascular outcomes data for Praluent alirocumab and a fresh cost-effectiveness analysis from the Institute for Clinical and Economic Review (ICER), Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have a proposition for payers:...
BioCentury | Oct 13, 2017
Clinical News

End of the road for Merck's anacetrapib

Merck & Co. Inc. (NYSE:MRK) said it will not seek regulatory approval of anacetrapib (MK-0859) to treat coronary heart disease (CHD). Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. Although anacetrapib met the primary...
BioCentury | Oct 12, 2017
Clinical News

End of the road for Merck's anacetrapib

Merck & Co. Inc. (NYSE:MRK) said it will not seek regulatory approval of anacetrapib (MK-0859) to treat coronary heart disease (CHD). Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. Although anacetrapib met the primary...
BioCentury | Oct 3, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Typhoid Cell culture and zebrafish studies suggest inhibiting cholesterol uptake in host cells could help treat Salmonella enterica serovar Typhi infection. In HeLa cells challenged with S. typhi , a tool compound that lowers cholesterol...
Items per page:
1 - 10 of 161